To investigate whether the SIRT1 inhibitor EX527 showed synergistic anticancer effects when used in combination with cisplatin or erlotinib, H358 cells were treated with EX527 combined with cisplatin or erlotinib. The IC50 values in cells treated with EX527 and either cisplatin or erlotinib indicated significant sensitization compared with those in each single treatment group (Supplementary Fig. 24a)....Collectively, these results indicate that the SIRT1 inhibitor EX527 has potential as an adjuvant therapy for reducing chemoresistance in KRASMut-driven cancers.